IXICO awarded four contracts worth a combined value of over £3m

IXICO today announces that it has recently been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over £3.0m.

The contracts are for global clinical trials of novel drugs for Alzheimer’s disease which span the three major phases of drug development and are expected to run for the next two to four years, subject to the drugs successfully progressing through the clinical trials process. They will utilise IXICO’s expertise in the Alzheimer’s field and our proprietary TrialTracker® and Assessa® digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.

By |2017-10-10T16:44:41+00:0018 January 2016|Contracts|